Prescription drug · NDA
Maxidex (dexamethasone) NDC 82667-600
Dexamethasone 1 mg/mL · For suspension · Ophthalmic · Harrow Eye, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 82667-600-05 | 82667060005 | 1 BOTTLE, PLASTIC in 1 CARTON (82667-600-05) / 5 mL in 1 BOTTLE, PLASTICMarketed from Apr 7, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Maxidex
- Generic name (nonproprietary)
- dexamethasone
- Active ingredients
- Dexamethasone — 1 mg/mL
- Dosage form
- For suspension
- Route
- Ophthalmic
- Labeler
- Harrow Eye, LLC
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 013422
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 82667-600_34661206-e37a-6ce7-e063-6394a90aaf85SPL ID 34661206-e37a-6ce7-e063-6394a90aaf85SPL set ID 35e47fcd-e020-43e5-8322-41f8060d220dRxCUI 205669, 309692UNII 7S5I7G3JQLUPC 0382667600053
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N482667060005followed by a unit qualifier and the quantityPackage 82667-0600-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.
Excerpt only. Read the full label for complete information.